Abstract: A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.
Type:
Application
Filed:
August 16, 2012
Publication date:
December 6, 2012
Applicants:
NIPPON ZENYAKU KOGYO CO., LTD., INCORPORATED NATIONAL UNIVERSITY IWATE UNIVERSITY
Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
Abstract: A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.
Type:
Grant
Filed:
July 20, 2007
Date of Patent:
September 18, 2012
Assignees:
Incorporated National University Iwate University, Nippon Zenyaku Kogyo Co., Ltd.
Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.
Abstract: This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the attenuated canine adenovirus type 2 strain obtained by adapting the canine adenovirus type 2 F1 strain in cultured cells to attenuate the same, and an attenuated canine parvovirus strain obtained by adapting the canine parvovirus F3 strain in cultured cells to attenuate the same.
Abstract: The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine.
Type:
Application
Filed:
October 31, 2008
Publication date:
September 30, 2010
Applicants:
NIPPON ZENYAKU KOGYO CO., LTD., OSAKA UNIVERSITY
Inventors:
Toshihiro Tsukui, Ken Ishii, Shizuo Akira, Cevayir Coban
Abstract: ?-Aminobutyric acid is supplied to animal efficiently and inexpensively to effectively enhance stress-relieving effect on the animal. Livestock are allowed to lick ?-Aminobutyric acid mixed with molasses and solidified into feedstuff blocks, so that ?-aminobutyric acid is supplied to livestock together with molasses.
Abstract: To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations.
Abstract: Disclosed is infusion for mastitis which contains a main ingredient, medium-chain fatty acid monoglyceride and an oily base wherein diffusivity and dispersivity of the main ingredient are improved by the monoglyceride to enhance dissolubility and thus absorbency of the main ingredient. In comparison with conventional infusions for mastitis, the infusion has immediate effectivity and is short in residual term; the main ingredient is expected to be utilized effectively and without waste.